Benzoyl peroxide
RTECS #
DM8575000
CAS #
Updated
March 2019
Molecular Weight
242.24
Molecular Formula
C14H10O4
Synonyms
Acnegel
Aztec BPO
Benzoperoxide
Benzoyl peroxide (ACGIH:OSHA)
Benzoyl superoxide
Benzoylperoxid (German)
Benzoylperoxyde (Dutch)
BZF-60
Cadat BPO
Cadox B-CH 50
Cadox BS
Debroxide
Dibenzoyl peroxide
Dibenzoylperoxid (German)
Dibenzoylperoxyde (Dutch)
Diphenylglyoxal peroxide
Fostex
Garox
Incidol
Loroxide
Lucidol
Luperco AA
Luperco AST
Luperox FL
Nayper B and BO
Norox bzp-250
Norox bzp-C-35
Novadelox
Oxylite
Panoxyl
Perossido di benzoile (Italian)
Peroxide, dibenzoyl
Peroxyde de benzoyle (French)
Persadox
Quinolor compound
Superox 744
Theraderm
Topex
Vanoxide
Xerac
Aztec BPO
Benzoperoxide
Benzoyl peroxide (ACGIH:OSHA)
Benzoyl superoxide
Benzoylperoxid (German)
Benzoylperoxyde (Dutch)
BZF-60
Cadat BPO
Cadox B-CH 50
Cadox BS
Debroxide
Dibenzoyl peroxide
Dibenzoylperoxid (German)
Dibenzoylperoxyde (Dutch)
Diphenylglyoxal peroxide
Fostex
Garox
Incidol
Loroxide
Lucidol
Luperco AA
Luperco AST
Luperox FL
Nayper B and BO
Norox bzp-250
Norox bzp-C-35
Novadelox
Oxylite
Panoxyl
Perossido di benzoile (Italian)
Peroxide, dibenzoyl
Peroxyde de benzoyle (French)
Persadox
Quinolor compound
Superox 744
Theraderm
Topex
Vanoxide
Xerac
Skin and Eye Irritation and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
eye /rabbit | 500 mg/24H | mild | 85JCAE -,324,1986 |
skin /human | 5%/48H | ADVEA4 34,68,1996 | |
skin /human | 5%/8W- intermittent | severe | ADVEA4 62,458,1982 |
skin /human | 0.5% | CODEDG 61,209,2009 | |
skin /woman | 1% | moderate | CODEDG 57,386,2007 |
Mutation Data and Reference
System Test | Route/Organism/Tissue | Dose | Reference |
---|---|---|---|
DNA Damage | other cell types/human | 100 µmol/L | CNREA8 45,2522,1985 |
DNA Damage | other cell types/mouse | 1 µmol/L | PAACA3 24,108,1983 |
DNA Damage | skin/mouse | 242 mg/kg/4W- intermittent | CRNGDP 25,431,2004 |
DNA inhibition | other cell types/human | 56 µmol/L | CNREA8 45,2522,1985 |
DNA repair | /Escherichia coli | 250 µg/well | MUREAV 133,161,1984 |
morphological transform | fibroblast/mouse | 0.1 µmol/L/21D (-enzymatic activation step) | EMMUEG 37,231,2001 |
mutation in mammalian somatic cells | kidney/human | 300 µmol/L | CRNGDP 13,1783,1992 |
other mutation test systems | other cell types/human | 56 µmol/L | CNREA8 45,2522,1985 |
specific locus test | fibroblast/mouse | 25 µmol/L/5W | MUREAV 577S,1,2005 |
Unscheduled DNA Synthesis | liver/rat | 100 pmol/L | CRNGDP 5,1547,1984 |
Tumorigenic Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
skin/mouse | lowest published toxic dose: 24 gm/kg/30W- intermittent | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Skin and Appendages: Tumors | SCIEAS 213,1023,1981 |
skin/mouse | lowest published toxic dose: 64000 mg/kg/40W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Skin and Appendages: Tumors Tumorigenic: Facilitates action of known carcinogens | CRNGDP 21,811,2000 |
skin/mouse | lowest published toxic dose: 28800 mg/kg/18W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Skin and Appendages: Tumors Tumorigenic: Facilitates action of known carcinogens | ARTODN 78,139,2004 |
Acute Toxicity Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
In Vitro/Human, leukemia cells | Inhibitor Concentration (5 percent kill): 15.5 mg/L/30M | In Vitro Toxicity Studies: Cell counting | TIVIEQ 27,857,2013 |
In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 3.5 mg/L/30M | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,857,2013 |
In Vitro/Human, leukemia cells | Inhibitor Concentration (25 percent kill): 41.0 mg/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 26,1150,2012 |
In Vitro/Human, lymphocyte | Inhibitor Concentration (30 percent kill): 64 mg/L/45H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 29,901,2015 |
In Vitro/Human, lymphocyte | Inhibitor Concentration (50 percent kill): 28 mg/L/45H | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,901,2015 |
In Vitro/Human, monocyte | Inhibitor Concentration Low: 33.3 mg/L/2H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1233,2013 |
In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 567.6 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TXAPA9 245,281,2010 |
In Vitro/jrd | Inhibitor Concentration (50 percent kill): 11.2 mg/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 28,626,2014 |
intraperitoneal/mouse | lethal dose (50 percent kill): 147 mg/kg | VCVGK* -,542,1994 | |
intraperitoneal/rat | lethal dose (50 percent kill): 372.8 mg/kg | VCVGK* -,543,1994 | |
oral/mouse | lethal dose (50 percent kill): 1200 mg/kg | VCVGK* -,542,1994 | |
oral/rat | lethal dose (50 percent kill): 6400 mg/kg | VCVGK* -,542,1994 | |
oral/rat | lethal dose (50 percent kill): 7710 mg/kg | Lung, Thorax, or Respiration: Cyanosis Liver: Other changes Kidney, Ureter, and Bladder: Other changes in urine composition | ARCOC* JUN1982 |
skin/mammal (species unspecified) | lethal dose (50 percent kill): >1 gm/kg | KODAK* #900713 |
Other Multiple Dose Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
skin/mouse | lowest published toxic dose: 121120 µg/kg/4W- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | CRNGDP 25,431,2004 |
Reviews
Organization | Standard | Reference |
---|---|---|
American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 5 mg/m3 | DTLVS* TLV/BEI,2013 |
American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Not classifiable as a human carcinogen | DTLVS* TLV/BEI,2013 |
International Agency for Research on Cancer (IARC) | Cancer Review:Animal Limited Evidence | IMEMDT 71,345,1999 |
International Agency for Research on Cancer (IARC) | Cancer Review:Animal Inadequate Evidence | IMEMDT 36,267,1985 |
International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 36,267,1985 |
International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 71,345,1999 |
International Agency for Research on Cancer (IARC) | Cancer Review:Group 3 | IMEMDT 71,345,1999 |
TOXICOLOGY REVIEW | CMTVAS 10(3),49,1973 | |
TOXICOLOGY REVIEW | MUREAV 488,151,2001 | |
TOXICOLOGY REVIEW | EMMUEG 43,143,2004 | |
TOXICOLOGY REVIEW | BPCEM* 17,237,2003 | |
TOXICOLOGY REVIEW | MUREAV 533,153,2003 | |
TOXICOLOGY REVIEW | DERCL* 27,289,2009 | |
TOXICOLOGY REVIEW | TXAPA9 243,239,2010 | |
TOXICOLOGY REVIEW | RTOPDW 61,1,2011 | |
TOXICOLOGY REVIEW | VETOX* ,339,2018 | |
TOXICOLOGY REVIEW | VETOX* ,357,2018 |
Standards and Regulations
Organization | Standard | Reference |
---|---|---|
Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 5 mg/m3 | DTLVS* 3,23,1971 |
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
Occupational Exposure Limit-AUSTRALIA | time-weighted average 5 mg/m3, JUL2008 | |
Occupational Exposure Limit-AUSTRIA | MAK-TMW 5 mg/m3;KZW 10 mg/m3, inhal, sen, 2007 | |
Occupational Exposure Limit-BELGIUM | time-weighted average 5 mg/m3, MAR2002 | |
Occupational Exposure Limit-DENMARK | time-weighted average 5 mg/m3, MAY2011 | |
Occupational Exposure Limit-FINLAND | time-weighted average 5 mg/m3, short term exposure limit 10 mg/m3, NOV2011 | |
Occupational Exposure Limit-FRANCE | VME 5 mg/m3, FEB2006 | |
Occupational Exposure Limit-GERMANY | MAK 5 mg/m3, inhal, 2011 | |
Occupational Exposure Limit-HUNGARY | time-weighted average 5 mg/m3, short term exposure limit 5 mg/m3, Skin, SEP2000 | |
Occupational Exposure Limit-ICELAND | time-weighted average 5 mg/m3, NOV2011 | |
Occupational Exposure Limit-JAPAN | s1 sen, MAY2012 | |
Occupational Exposure Limit-KOREA | time-weighted average 5 mg/m3, 2006 | |
Occupational Exposure Limit-MEXICO | time-weighted average 5 mg/m3, 2004 | |
Occupational Exposure Limit-NEW ZEALAND | time-weighted average 5 mg/m3, JAN2002 | |
Occupational Exposure Limit-NORWAY | time-weighted average 5 mg/m3, JAN1999 | |
Occupational Exposure Limit-PERU | time-weighted average 5 mg/m3, JUL2005 | |
Occupational Exposure Limit-POLAND | MAC(time-weighted average) 5 mg/m3, MAC(short term exposure limit) 10 mg/m3, JAN1999 | |
Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 5 mg/m3, 2003 | |
Occupational Exposure Limit-THE PHILIPPINES | time-weighted average 5 mg/m3, JAN1993 | |
Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 5 mg/m3, OCT2007 | |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 5 mg/m3 | CFRGBR 29,1926.55,1994 |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 5 mg/m3 | CFRGBR 41,50-204.50,1994 |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 5 mg/m3 | CFRGBR 29,1910.1000,1994 |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 5 mg/m3 | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
Organization | Standard | Reference |
---|---|---|
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO BENZOYL PEROXIDE-air | 10H time-weighted average 5 mg/m3 | NIOSH* DHHS #92-100,1992 |
National Occupational Exposure Survey 1983 | Hazard Code 11280; Number of Industries 62; Total Number of Facilities 7331; Number of Occupations 75; Total Number of Employees Exposed 87420; Total Number of Female Employees Exposed 11192 | |
National Occupational Hazard Survey 1974 | Hazard Code 11280; Number of Industries 47; Total Number of Facilities 5255; Number of Occupations 42; Total Number of Employees Exposed 32909 |
Status in Federal Agencies
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health